Merck's sac-TMT extends survival in advanced endometrial cancer, gets FDA priority review

The US FDA has granted priority review to Merck's targeted drug sacituzumab tirumotecan after a 776-patient trial in recurrent endometrial cancer. Patients on the drug lived a median 19 months versus 12.1 months on chemotherapy, a 32% lower risk of death, and 35% saw tumours shrink. A regulatory decision is expected by June 2027.